Search Entries: Displaying 1 - 10 of 10 Master protocol trials for the development of oncology drugsSupervisor: Dr David RobertsonDepartment/InstituteMRC Biostatistics UnitIndustrial Partner:IQVIA Integrating genomic, multi-omic and clinical data at population scale to inform therapeutic targets and drug development programmesSupervisor: Professor Adam ButterworthDepartment/InstituteDepartment Public Health & Primary CareIndustrial Partner:AstraZeneca Centre for Genomics Research (CGR) Designing self-assembling multi-functional biomolecular condensates to sense disease causing proteins in the cell and target them for degradationSupervisor: Dr Janet Kumita, and Prof Laura ItzhakiDepartment/InstituteDepartment of PharmacologyIndustrial Partner:Transition Bio Uncovering novel negative regulators of T cell immunity to cancerSupervisor: Dr Rahul RoychoudhuriDepartment/InstituteDepartment of PathologyIndustrial Partner:AstraZeneca Characterisation of antigenic targets involved in Chlamydia trachomatis infection identified by phenotypic phage displaySupervisor: Dr Richard HaywardDepartment/InstituteDepartment of PathologyIndustrial Partner:AstraZeneca Development and optimisation of LC-MS/MS based methods for plasma peptide and protein analysisSupervisor: Dr Richard KayDepartment/InstituteInstitute of Metabolic ScienceIndustrial Partner:Drug Development Solutions Limited Exploring peripheral actions of targeting GIPRSupervisor: Professor Fiona GribbleDepartment/InstituteInstitute of Metabolic ScienceIndustrial Partner:AstraZeneca Using human genetics to identify neurodegenerative disorders likely to be alleviated by blocking SARM1Supervisor: Professor Michael ColemanDepartment/InstituteDepartment of Clinical NeurosciencesIndustrial Partner:AstraZeneca RF coils for human 11.7T metabolic MRISupervisor: Professor Chris RodgersDepartment/InstituteDepartment of Clinical NeurosciencesIndustrial Partner:PulseTeq Limited Phase transitions go viral: targeting viral replication through modulation of biomolecular condensatesSupervisor: Dr Alexander BorodavkaDepartment/InstituteDepartment of BiochemistryIndustrial Partner:Transition Bio